The U.K.’s National Institute for Health and Care Excellence (NICE) in a final draft guidance recommended EUSA Pharma’s Qarziba, a neuroblastoma treatment, pharmaphorum reports.
NICE’s recommendation comes after a first draft guidance this year in which the government body floated Qarziba could receive funding from the Cancer Drugs Fund on an interim basis.
The drugmaker also agreed to trim the drug’s price, according to the report.
The Scottish Medicines Consortium is also conducting a separate review of Qarziba, and is expected to make its recommendation this year.
According to pharmaphorum’s report, about 100 children are diagnosed with neuroblastoma each year.